Literature DB >> 6126422

Effects of cirrhosis and ageing on the elimination and bioavailability of ranitidine.

C J Young, T K Daneshmend, C J Roberts.   

Abstract

The plasma concentrations of ranitidine after oral and intravenous administration have been measured in 10 healthy young adults, nine cirrhotic patients, and eight healthy elderly people. In the first of these bioavailability was 51 +/- 4% and half life 161 +/- 11 minutes after oral and 124 +/- 5 minutes after intravenous administration. In the cirrhotics bioavailability was increased to 70 +/- 7%, clearance was reduced, and there was a modest increase in half life. In the elderly bioavailability was similar to that in young adults, clearance was markedly reduced, and half life was prolonged to 241 +/- 7 minutes after oral and 194 +/- 11 minutes after intravenous administration. It is predicted that blood levels in cirrhotics and the elderly would be 50 to 60% higher than in healthy young adults after repeated oral administration of similar doses.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6126422      PMCID: PMC1419822          DOI: 10.1136/gut.23.10.819

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  11 in total

Review 1.  Factors influencing antipyrine elimination.

Authors:  I H Stevenson
Journal:  Br J Clin Pharmacol       Date:  1977-06       Impact factor: 4.335

Review 2.  Hepatic first-pass metabolism in liver disease.

Authors:  T F Blaschke; P C Rubin
Journal:  Clin Pharmacokinet       Date:  1979 Nov-Dec       Impact factor: 6.447

3.  Decreased first-pass metabolism of labetalol in chronic liver disease.

Authors:  M Homeida; L Jackson; C J Roberts
Journal:  Br Med J       Date:  1978-10-14

4.  The effect of age on plasma levels of propranolol and practolol in man.

Authors:  C M Castleden; C M Kaye; R L Parsons
Journal:  Br J Clin Pharmacol       Date:  1975-08       Impact factor: 4.335

5.  Antipyrine disposition and liver size in the elderly.

Authors:  C G Swift; M Homeida; M Halliwell; C J Roberts
Journal:  Eur J Clin Pharmacol       Date:  1978-11-16       Impact factor: 2.953

6.  Pharmacokinetics of the H2- receptor antagonist ranitidine in man.

Authors:  J J McNeil; G W Mihaly; A Anderson; A W Marshall; R A Smallwood; W J Louis
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

7.  The relationship between liver volume, antipyrine clearance and indocyanine green clearance before and after phenobarbitone administration in man.

Authors:  C J Roberts; L Jackson; M Halliwell; R A Branch
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

Review 8.  Pharmacokinetics in the elderly.

Authors:  J Crooks; K O'Malley; I H Stevenson
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

9.  Effect of age and sex on human drug metabolism.

Authors:  K O'Malley; J Crooks; E Duke; I H Stevenson
Journal:  Br Med J       Date:  1971-09-11

10.  Ranitidine--a new H2-receptor antagonist.

Authors:  E P Woodings; G T Dixon; C Harrison; P Carey; D A Richards
Journal:  Gut       Date:  1980-03       Impact factor: 23.059

View more
  21 in total

Review 1.  Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations.

Authors:  J H Lin
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics in patients with liver disease.

Authors:  A J McLean; D J Morgan
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

4.  Frequent non-response to histamine H2-receptor antagonists in cirrhotics.

Authors:  S Walker; D R Krishna; U Klotz; J C Bode
Journal:  Gut       Date:  1989-08       Impact factor: 23.059

Review 5.  Guide to drug dosage in hepatic disease.

Authors:  N M Bass; R L Williams
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

6.  Modulation of the tight junctions of the Caco-2 cell monolayers by H2-antagonists.

Authors:  L S Gan; S Yanni; D R Thakker
Journal:  Pharm Res       Date:  1998-01       Impact factor: 4.200

7.  Pharmacokinetics and bioavailability of ranitidine in normal subjects and cirrhotic patients.

Authors:  M Morichau-Beauchant; G Houin; P Mavier; C Alexandre; D Dhumeaux
Journal:  Dig Dis Sci       Date:  1986-02       Impact factor: 3.199

Review 8.  Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  S M Grant; H D Langtry; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

Review 9.  Clinical pharmacokinetics of ranitidine.

Authors:  C J Roberts
Journal:  Clin Pharmacokinet       Date:  1984 May-Jun       Impact factor: 6.447

Review 10.  Prescribing policy for antiulcer treatment in the elderly.

Authors:  G Bianchi Porro; M Lazzaroni
Journal:  Drugs Aging       Date:  1993 Jul-Aug       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.